Cambridge Healthtech Institute’s Fifth Annual
Antibodies for Cancer Therapy
Exploiting Successful Strategies
Part of the 11th Annual PEGS: the essential protein engineering summit
May 4-5, 2015 | World Trade Center | Boston, Massachusetts

The outlook for therapeutic antibodies is very promising. This meeting will highlight current trends in development including identifying and validating novel targets, improving drug-like properties, employing immunotherapy approaches and advancing novel constructs. This program has consistently recruited top thought leaders in the field to review the status of myriad innovative antibodies and key ideas for advancing them towards the clinic.


How to Best Launch a New Platform

Tillman U. Gerngross, Ph.D., Professor, Engineering; Associate Provost, Entrepreneurship & Technology Transfer, Thayer School of Engineering at Dartmouth; Co-Founder and CEO, Adimab

Targeting Cancer Stem Cells

Robert A. Weinberg, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor, Biology, Massachusetts Institute of Technology

What Are the Challenges and How Do We Overcome Them? 

KEYNOTE PRESENTATION: Talk Title to be Announced

Bahija Jallal, Ph.D., Executive Vice President, MedImmune

Human Anti-CCR4 mAb Reverses Immunosuppression and Restores Anti-Tumor Immunity

Wayne A. Marasco, M.D., Ph.D., Professor, Medicine, Harvard Medical School

Intratumoral Gene-Therapy with IL-12 to Enhance Responses to Immune “Checkpoint” Therapy

Robert H. Pierce, M.D., CSO, OncoSec Medical, Inc.

Biomarker Development in Immune Therapies for Oncology

Jennifer H. Yearley, D.V.M., Ph.D., DACVP, Principal Scientist, Profiling and Expression, Merck Research Laboratories

Combination Therapy

F. Stephen Hodi, M.D., Director, Melanoma Disease Center & Center for Immuno-Oncology, Dana-Farber Cancer Institute

Program on PDL1

Helen Sabzevari, Ph.D., Global Head, Oncology & Immunotherapy, EMD Serono Research Institute

KEYNOTE PRESENTATION: Antibody Targeted Cancer Immunotherapy

Louis M. Weiner, M.D., Director, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Identification and Translation of Optimal Immunotherapy Combinations

Michael A. Curran, Ph.D., Assistant Professor, Immunology, University of Texas MD Anderson Cancer Center


A Novel Calicheamicin-Based ADC for Solid Tumors

Marc I. Damelin, Ph.D., Senior Principal Scientist, Oncology Research Unit, Pfizer, Inc.


Patritumab- anti-HER3 mAb for Non-Small Cell Lung Cancer (NSCLC)

Robert A. Beckman, M.D., Executive Director, Clinical Development Oncology, Daiichi Sankyo Pharmaceutical Development


KEYNOTE PRESENTATION: Mesothelin: An Important Target for Cancer Immunotherapy

Ira Pastan, M.D., NIH Distinguished Investigator, Co-Chief, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health

Emerging Immune Checkpoint Targets for Cancer Immunotherapy

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology Medicine, Albert Einstein College of Medicine

Single-Domain Antibodies from Sharks: Utility and Basic Science

Martin F. Flajnik, Ph.D., Professor, Microbiology and Immunology, University of Maryland, Baltimore

For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5464

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471